Beranda › Kanker Lambung › Arizona
Uji klinis Kanker Lambung di Arizona
13 studi untuk Kanker Lambung mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Cancer Center at Saint Joseph's, Phoenix
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Mayo Clinic in Arizona - Phoenix, Phoenix
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07221149Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Mayo Clinic, Phoenix
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07700979A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- HonorHealth Research Institute, Scottsdale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07705334Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Phoenix
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07431281A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Mayo Clinic Arizona, Phoenix
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07070232Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #132, Phoenix
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jul 2026 · NCT06974110A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Mayo Clinic Hospital, Phoenix
- Mayo Clinic, Scottsdale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06131840Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1016, Goodyear
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT07432295A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Phoenix
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06395519SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- HonorHealth Research Institute, Scottsdale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Feb 2024 · NCT04282044Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.